Savolitinib (AZD-6094) is a potent and selective, oral bioavailability inhibitor with ICs of 5 nM and 3 nM for c-Met and p-Met, respectively.Savolitinib (AZD-6094) selectively binds and inhibits c-Met activation in an ATP-competitive manner, disrupting the c-Met signaling pathway. It has anti-tumor activity.